All In Biotech

Drug Trial Radar · NCT03350451

An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1

A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1

Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Apr 4, 2018

Primary completion

Feb 7, 2023

Study completion Feb 7, 2023

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Nov 22, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety and tolerability of lumasiran in participants with Primary Hyperoxaluria Type 1.

Conditions

  • PH1
  • Primary Hyperoxaluria
  • RNAi Therapeutic
  • siRNA
  • AGT

Interventions

  • LumasiranDrug

    Multiple doses of lumasiran by SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With at Least One Adverse Event (AE)Time frame: Baseline (Day -1) up to 54 months

Locations

9 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Bordeaux, France

  • Clinical Trial Site

    Lyon, France

  • Clinical Trial Site

    Paris, France

  • Clinical Trial Site

    Bonn, Germany

  • Clinical Trial Site

    Haifa, Israel

  • Clinical Trial Site

    Jerusalem, Israel

  • Clinical Trial Site

    Amsterdam, Netherlands

  • Clinical Trial Site

    Birmingham, United Kingdom

  • Clinical Trial Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.